Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

Pharmacoecon Open. 2023 Jan;7(1):47-48. doi: 10.1007/s41669-022-00366-y.
No abstract available

Publication types

  • Published Erratum